Entity

Time filter

Source Type

Mexico City, Mexico

Cruz-Benitez L.,Servicio de Cirugia Oncologica | Cortes-Cardenas S.A.,Servicio de Cirugia Oncologica | Farias-Alarcon M.A.,Servicios Modulares | Tenorio-Torres J.A.,CMN 20 de Noviembre | And 2 more authors.
Gaceta Mexicana de Oncologia | Year: 2011

Introduction: Myxoid fibrosarcoma or Evans' tumor is an aggressive sarcoma of fibroblastic origin. Histologically, it contains a myxoid matrix. Objective: To report a case of a low-grade myxoid fibrosarcoma and to perform a bibliographic review of the condition. Case Description: A 36 year-old male patient, whose disease started 20 years ago with enlargement of the right lumbosacral region and increased pain with active motion. Computed tomography (CT) showed a 10 x 15 cm right lumbosacral tumor. The patient underwent surgery at some other facility, where wide resection of the tumor was performed and fibromyxoid sarcoma diagnosis was made. The patient was sent to assessment for adjuvant radiotherapy and a 66 Gy total dose radiation therapy was scheduled; however, he did not attend the appointment and was subsequently assessed on November 11 2010 when a 35 x 40 cm, lobulated, exophytic tumor fixed to the lumbar spine was detected in the lumbosacral region. In November 2010, the patient underwent surgery consisting of wide resection of the tumor, facet denervation, and flaps rotation. The pathology report was fibromyxoid sarcoma with surgical margins infiltrated by the tumor. The immunohistochemical report stated the tumor was positive both to vimentin and muscle-specific action. Discussion: Fibromyxoid sarcoma is a rare malignant neoplasm, with less than 150 cases reported worldwide. Hence, the purpose of reviewing this condition as its unusual presentation may lead to diagnostic confusion with other soft tissue sarcomas. Source


Serna-Camacho M.E.,Hospital Regional Lic. Adolfo Lopez Mateos ISSSTE | Cortes-Cardenas S.A.,CMN 20 de Noviembre
Gaceta Mexicana de Oncologia | Year: 2012

Malignant pleural mesothelioma is a neoplasm with high mortality of 99% at 5 years and with little prospect of treatment, facing different problems such as the rarity of the disease, the difficulty of staging, aggressive nature, little sensitivity to this combined chemotherapy aggressive surgical procedures that few patients can tolerate because of their age and suffer various diseases coomorbidas. The surgical procedures used are extrapleral pleurotomy and more pleurotomy pleurodesis decortication and yet all these procedures are palliative only limited control and high rates of recurrence as a single treatment. Has been offered other treatments such as conventional chemotherapy having little benefit with platinum-based schemes more pemetrexed giving a benefit of 3 months compared with platinum alone have survivals of four to 12 months. Attempts have been combining chemotherapy with other therapies such as anti angiogenic inhibitors tirosinkinasa, the use of immunosuppressants which have shown no benefit or is able to overcome the combination of pemetrexed with platinum. Source


Sanchez-Avila J.F.,INCMNSZ | Dehesa-Violante M.,Mexican Association of Hepatology | Mendez-Sanchez N.,Liver Research Unit | Bosques-Padilla F.,Hospital Universitario Je Gonzalez | And 16 more authors.
Annals of Hepatology | Year: 2015

Chronic hepatitis due to hepatitis C (HCV) viral infection is one of the main causes of chronic liver disease in the world. In the near future, the number of cases developing complications is expected to rise and include the following: liver cirrhosis, liver failure (ascites, encephalopathy, spontaneous bacterial peritonitis, variceal hemorrhage), hepatocellular carcinoma, death or the need for liver transplantation. However, research in the field of hepatitis C diagnosis and treatment is one of the most active specially on the development of new therapeutic strategies potentially offering better viral eradication rates and fewer adverse events. Although this disease is a frequent cause of consultation and hospitalization, data published in our country are insufficient. The last guidelines proposed by a medical association in Mexico were published in 2007 and those suggested by the General Council of Health were published in 2009. The aim of this study group was to analyze the available evidence on the diagnosis and treatment of hepatitis C in the Mexican population, in the context of published international clinical and therapeutic guidelines, in order to issue recommendations that are applicable in our midst. The Mexican Association of Hepatology convened a work group in Mexico City, on April 25th and 26th, 2014. Twenty specialists with particular interest and experience. © 2014 Annals of Hepatology. All rights reserved Source


Introduction: Breast Cancer, locally advanced-stage, requires a multidisciplinary treatment aimed at increasing overall survival in patients. Objective: To evaluate the complete pathological responses of patients under this treatment strategy. Methods: Patients with locally advanced breast cancer eligible to receive 4 cycles of chemotherapy to preoperative epirubicin and docetaxel 75 mg/m2 to 75 mg/m2 Day 1 every 3 week. Results: A total of 128 patients enrolled from June 2004 through January 2007 received 4 cycles of preoperative chemotherapy. The completed pathologic response rate was 32.5%; the persistent illness was 55.8% of the patients. The final clinical response was: 39.1% complete response, 40% partial response, 14.1% stable disease and 6.67% progressions. Survival time without progression presents a mean of 211.4 days and mean of 380 days in function with death survival. Of the 128 enrolled patients 3.9% died. Incidence of adverse events was 80.4% and of this 6.2% was serious adverse events and 3.13% of the same discontinued the study medication. By security, percentages of patients presenting the most frequently adverse events were: 72.6 alopecia, 60.9 nausea, 44.5 vomiting, 31.2 diarrhea and 24.2 asthenia. Conclusion: The combination of Epirubicin and Docetaxel is active and reaches complete pathological responses with a substantial and acceptable toxicity profile. Source


Rojano-Mejia D.,CMN 20 de Noviembre | Rojano-Mejia D.,Instituto Mexicano del Seguro Social | Coral-Vazquez R.M.,National Polytechnic Institute of Mexico | Coral-Vazquez R.M.,Institute Seguridad Y Servicios Sociales Of Los Trabajadores Del Estado | And 7 more authors.
Maturitas | Year: 2012

Objective: Osteoporosis is a complex health disease characterized by low bone mineral density (BMD), which is determined by an interaction of genetics with metabolic and environmental factors. The tumor necrosis factor receptor superfamily, member 11b (TNFRSF11B) gene, has been investigated in relation to BMD. Three polymorphisms in/nearby TNFRSF11B have been associated with BMD variations in some populations. The aim of this study was to investigate the possible association among three SNPs of TNFRSF11B and their haplotypes with the presence of BMD variations in postmenopausal Mexican Mestizo women. Subjects and methods: One thousand unrelated postmenopausal women of Mexican-Mestizo ethnic origin, who attended the outpatient clinic for routine, general medical evaluation, were invited and 750 women accepted to participate in the study. A structured questionnaire for risk factors was applied and BMD was measured in total hip and lumbar spine by dual-energy X-ray absorptiometry. DNA was obtained from blood leukocytes. Three single-nucleotide polymorphisms in TNFRSF11B gene were studied: rs4355801, rs2073618, and rs6993813. Real-time PCR allelic discrimination was used for genotyping. Deviations from Hardy-Weinberg equilibrium were tested. Pairwise linkage disequilibrium between single nucleotide polymorphisms was calculated by direct correlation r 2, and haplotype analysis was conducted. Results: Of the subjects, 31% had osteoporosis, 45.1% had osteopenia, and 23.9% had normal BMD. Genotype and allele distributions showed no significant differences; however, A-G-T haplotype was associated with variations in femoral neck BMD (P = 0.022). Conclusions: In our study population, analysis of the haplotypes of TNFRSF11B is a better genetic marker for variations in BMD. © 2011 Elsevier Ireland Ltd. All rights reserved. Source

Discover hidden collaborations